HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Development of skills for end-of-life discussions ‘a lifelong process’
• Provocative data reveal changing paradigms in prostate cancer Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA grants fast track designation to evofosfamide for advanced pancreatic cancer
• FDA grants fast track designation to sacituzumab govitecan for NSCLC
• FDA grants fast track status to AG-120 for IDH1-mutated AML
• FDA grants fast track status to luspatercept for beta-thalassemia
• FDA grants fast track status to TRC105 for metastatic renal cell carcinoma
• FDA grants orphan drug designation to Liposomal Grb-2 for AML
• FDA grants orphan drug designation to Triolimus for angiosarcoma
• 9-valent HPV vaccine noninferior to quadrivalent HPV vaccine
• Clinical data indicate patient-specific risks for chemotherapy-related hospitalization
• Hodgkin’s lymphoma survivors face high risk for cardiovascular diseases
• Improved AML prognosis with NPM1-positive FLT3-ITD-negative genotype contingent upon patient age
• Investigation programs needed for study of risks in use of pediatric anticoagulant drugs
• Late mortality rates have declined in pediatric cancer survivors
• LUSI: Early recall rates decline in subsequent lung cancer screenings
• Sickle cell disease increases mortality risk during pregnancy
• TITRe2: Restrictive transfusion threshold not superior to liberal strategy after cardiac surgery
• ASH awards ‘bridge grants’
• Cancer center director receives award
• Center director receives award
• Magazine recognizes ‘extraordinary’ nurse
• Urological society presents Distinguished Service Award
• Oncology nurses showcase ‘passion for excellence’ at 40th ONS Congress Paula T. Rieger, RN, MSN, CAE, FAAN
• Anastrozole prolongs breast cancer-free survival following DCIS diagnosis
• Aspirin provides survival benefit as secondary preventative measure in colorectal cancer
• Docetaxel improves survival for men with hormone-naive prostate cancer
• Eribulin improves survival for patients with advanced liposarcoma, leiomyosarcoma
• Findings support wider excision margins in melanoma
• Margin shaving reduces positive margins, need for additional surgery in breast cancer
• Mutational load predicts progression in patients with Barrett's esophagus
• Nivolumab-based treatments slow progression of melanoma
• Pembrolizumab demonstrates efficacy in advanced head and neck cancers
• Radiotherapy plus hormone therapy improves PFS after radical prostatectomy
• Speaker: Cost of cancer drugs a 'major problem'
• Host genetic variants as predictors of chemotherapy-related toxicity in children with ALL: Personalizing the benefit–risk balance Jai N. Patel, PharmD, BCOP, CPP